Vericel Corporation

VCEL

US92346J1088

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2026-02-13 pm EST			5-day change	1st Jan Change
35.96 ^USD	+5.86%		-0.64%	-0.14%

Jan. 13	Vericel Corporation Provides Preliminary Unaudited Earnings Guidance for the Fourth Quarter and Full Year of 2025	CI
Jan. 13	Vericel Reports Preliminary 2025 Net Revenue	MT

Vericel Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025

Published on 07/31/2025 at 11:38 am EDT - Modified on 07/31/2025 at 08:08 am EDT

S&P Capital IQ

VERICEL CORPORATION

+5.86%

Vericel Corporation reported earnings results for the second quarter and six months ended June 30, 2025. For the second quarter, the company reported revenue was USD 63.24 million compared to USD 52.66 million a year ago. Revenue was USD 63.24 million compared to USD 52.66 million a year ago. Revenue was USD 63.24 million compared to USD 52.66 million a year ago. Revenue was USD 63.24 million compared to USD 52.66 million a year ago. Net loss was USD 0.553 million compared to USD 4.68 million a year ago. Net loss was USD 0.553 million compared to USD 4.68 million a year ago. Net loss was USD 0.553 million compared to USD 4.68 million a year ago. Net loss was USD 0.553 million compared to USD 4.68 million a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.1 a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.1 a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.1 a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.1 a year ago. Diluted loss per share from continuing operations was USD 0.01 compared to USD 0.1 a year ago. Diluted loss per share from continuing operations was USD 0.01 compared to USD 0.1 a year ago. Diluted loss per share from continuing operations was USD 0.01 compared to USD 0.1 a year ago. Diluted loss per share from continuing operations was USD 0.01 compared to USD 0.1 a year ago.
For the six months, revenue was USD 115.84 million compared to USD 103.94 million a year ago. Revenue was USD 115.84 million compared to USD 103.94 million a year ago. Revenue was USD 115.84 million compared to USD 103.94 million a year ago. Revenue was USD 115.84 million compared to USD 103.94 million a year ago. Net loss was USD 11.8 million compared to USD 8.54 million a year ago. Net loss was USD 11.8 million compared to USD 8.54 million a year ago. Net loss was USD 11.8 million compared to USD 8.54 million a year ago. Net loss was USD 11.8 million compared to USD 8.54 million a year ago. Basic loss per share from continuing operations was USD 0.24 compared to USD 0.18 a year ago. Basic loss per share from continuing operations was USD 0.24 compared to USD 0.18 a year ago. Basic loss per share from continuing operations was USD 0.24 compared to USD 0.18 a year ago. Basic loss per share from continuing operations was USD 0.24 compared to USD 0.18 a year ago. Diluted loss per share from continuing operations was USD 0.24 compared to USD 0.18 a year ago.

Latest news about Vericel Corporation

Jan. 13	Vericel Corporation Provides Preliminary Unaudited Earnings Guidance for the Fourth Quarter and Full Year of 2025	CI
Jan. 13	Vericel Reports Preliminary 2025 Net Revenue	MT
Dec. 18	Truist Securities Adjusts Price Target on Vericel to $45 From $50, Maintains Buy Rating	MT
Nov. 10	Truist Raises Price Target on Vericel to $50 From $41, Keeps Buy Rating	MT
Nov. 06	Vericel Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
Nov. 06	Vericel Swings to Q3 Earnings, Revenue Rises	MT
Nov. 06	Earnings Flash (VCEL) Vericel Posts Q3 EPS $0.10, vs. FactSet Est of $0.01 Loss	MT
Nov. 06	Earnings Flash (VCEL) Vericel Corporation Reports Q3 Revenue $67.5M, vs. FactSet Est of $64.6M	MT
Nov. 06	Sports and burn therapies firm Vericel Q3 revenue beats estimates	RE
25-09-18	North American Morning Briefing : Stocks Poised to Open Higher After Rates Cut -2-	DJ
25-09-17	Vericel Shares Lower After BTIG Downgrade	MT
25-07-31	Vericel Corporation, Q2 2025 Earnings Call, Jul 31, 2025
25-07-31	Vericel Q2 Net Loss Narrows, Revenue Rises; Shares Fall	MT
25-07-31	Vericel Corporation Reaffirms Earnings Guidance for the Year 2025	CI
25-07-31	Biologics company Vericel's Q2 revenue misses expectations	RE

Chart Vericel Corporation

Duration

Period

VCEL: Dynamic Chart

Company Profile

Vericel Corporation is a fully-integrated, commercial-stage biopharmaceutical company. The Company is a provider of advanced therapies for the sports medicine and severe burn care markets. It markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The Company also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adults with deep partial-thickness and/or full-thickness burns.

Employees

357

Sector

Pharmaceuticals

Calendar

Feb. 25 - Q4 2025 Earnings Release

More about the company